SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sonis ST,Elting LS,Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100: 19952025.
  • 2
    Vera-Llonch M,Oster G,Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006; 106: 329336.
  • 3
    Trotti A,Bellm LA,Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66: 253262.
  • 4
    Bentzen SM,Saunders MI,Dische S, et al. Radiotheraphy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol. 2001; 60: 123135.
  • 5
    Stokman MA,Sonis ST,Dijkstra PV, et al. Assessment of oral mucositis in clinical trials: impact of training on evaluations in a multi-centre trial. Eur J Cancer. 2005; 41: 17351738.
  • 6
    Posner MR,Hershock DM,Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 17051715.
  • 7
    Vermorken JB,Remenar E,van Herpen C, et al. Cisplatin, fluorouracil, and docetaxil in unresectable head and neck cancer. N Engl J Med. 2007; 357: 16951704.
  • 8
    Stiff PJ,Erder H,Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006; 37: 393401.
  • 9
    Epstein JB,Beaumont JL,Gwede CK, et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer. 2007; 109: 19141922.
  • 10
    Murphy BA,Gilbert J,Cmelak A, et al. Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol. 2007; 5: 807822.
  • 11
    Duncan GG,Epstein JB,Tu D, et al; National Cancer Institute of Canada Clinical Trials Group. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005; 27: 421428.
  • 12
    Elting LS,Cooksley CD,Chambers MS, et al. Risk, outcomes, and cost of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007; 68: 110120.
  • 13
    Stiff PJ,Emmanouilides C,Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol. 2006; 24: 51865193.
  • 14
    Cella DF,Tulsky DS,Gary G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570579.
  • 15
    Bonomi AE,Cella DE,Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996; 5: 309320.
  • 16
    Lai JS,Cella D,Chang CH, et al. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create and store a core item back from the FACIT Fatigue Scale. Qual Life Res. 2003; 12: 485501.
  • 17
    Brucker PS,Yost K,Cashy J, et al. General population of cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005; 28: 192211.
  • 18
    Brucker PS,Yost K,Cash J, et al. Normative reference values for the FACT-G. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System Manual. Chicago, IL: Evanston Northwestern Healthcare. Version 4, 2005.
  • 19
    Fromme EK,Eilers KM,Mori M, et al. How accurate is clinician reporting of chemotherapy adverse events? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004; 22: 34853490.
  • 20
    Chao KS,Ozyigit G,Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004; 59: 4350,
  • 21
    Yao M,Karnell LH,Funk GF, et al. Health-related quality-of-life outcomes after IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2007; 69: 13541360.
  • 22
    Lee NY,de Arruda FF,Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 966974.
  • 23
    Rose-Ped AM,Bellm LA,Epstein JB, et al. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs. 2002; 25: 461467.
  • 24
    Peterman A,Cella D,Glandon D, et al. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr. 2001; 29: 4551.
  • 25
    Cella D,Hahn EA,Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002; 11: 207221.
  • 26
    Yost KJ,Sorensen MV,Hahn EA,Glendenning GA,Gnanasakthy A,Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005; 8: 117127.
  • 27
    Patrick DL,Gagnon DD,Zagari MJ, et al. Assessing the clinical significance of health-related qualify of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003; 39: 335345.
  • 28
    Cella D,Eton DT,Lai JS, et al. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue scales. J Pain Symptom Manage. 2002; 24: 547561.
  • 29
    Eton D,Yost K. Minimally Important Differences on the Functional Assessment of Chronic Illness Therapy Instruments. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System Manual. Chicago, IL: Evanston Northwestern Healthcare, Version 4, 2005.